JAKAVI relieved burdensome symptoms of PV and improved quality of life (QoL)1-3
Provided consistent, clinically meaningful improvement of the most commonly reported PV symptoms1,2
Change in symptom scores (MPN-SAF) from baseline to Week 321

- Change in symptom scores at Week 32 was an exploratory endpoint4
JAKAVI provided rapid and sustained relief of pruritus4
- More than 4 times as many patients receiving JAKAVI reported that pruritus was "much improved" or "very much improved" compared with those receiving BAT4
- 40% with JAKAVI vs 9.9% with BAT at Week 4
- 58.2% with JAKAVI vs 12.5% with BAT at Week 32
JAKAVI provided clinically meaningful improvement of health-related QoL3
Global health status/quality-of-life score (EORTC QLQ-C30) over time3

- Change in EORTC QLQ-C30 score at each visit was an exploratory endpoint4
- JAKAVI improved QoL across EORTC QLQ-C30 functional domains3
- Role functioning
- Physical functioning
- Emotional functioning
- Cognitive functioning
- Social functioning
Improvements with JAKAVI were seen as soon as Week 4, maintained at least through Week 32, and observed across functional domains3